PreciseDx, the NYC-based supplier of PreciseBreast, a breast most cancers diagnostic that’s empowered by OncoIntelligence, its proprietary AI-platform, raised $11M in extra fundin.
The spherical was led by Eventide Asset Administration, Merck World Well being Innovation Fund and Philips Ventures and included Labcorp, Quest Diagnostics, GenHenn Capital Enterprise, together with different present buyers.
The corporate intends to make use of the funds to optimize its ongoing medical information assortment, industrial growth and planning for the 2026 launch of its flagship product.
PreciseDx gives PreciseBreast that’s designed particularly to hurry the method of care planning for breast most cancers sufferers. The take a look at gives complete perception into phenotype and grade to foretell the chance of recurrence inside hours. It makes use of OncoIntelligence, its AI-platform, to mix seven morphologic options with 4 medical components to supply a single OncoIntelligence Rating between 0 and 100.
PreciseBreast has been clinically validated by outstanding analysis establishments and in additional than 3,000 breast most cancers circumstances, for its potential to precisely and reliably stratify sufferers into two cohorts based mostly on threat of illness recurrence at six years.
FinSMEs
19/06/2025
